ESA REMS Allows Oncology Providers One Year To Enroll Before Possible Distribution Limits

The Risk Evaluation and Mitigation Strategy for erythropoiesis-stimulating agents announced by FDA Feb. 16 focuses on requiring health care providers to educate patients about the risks and benefits of treatment.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet